Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Health: Addiction

The Exceptional Women Alliance (EWA) congratulates Dymeka Harrison on next chapter

Leave a comment


“We are thrilled for Dymeka as she advances her career with this new opportunity where she will not only showcase her strategic leadership skills but will impact the greater community with early cancer screening options,” said Larraine Segil, Chair and CEO of EWA. “Anytime one of our EWA’s succeeds, we all succeed. We look forward to supporting Dymeka in her new endeavor!”

“EWA’s mission has been a guiding light in my life, personally and professionally. Their unwavering commitment to addressing the gender gap in leadership and providing holistic coaching has empowered countless women to reach new heights. As Larraine Segil’s legacy, EWA stands as a testament to the power of women supporting women on the less traveled road to success. EWA is not just an organization; it’s a community of peers – sisters dedicated to nurturing and uplifting each other on the journey to leadership and life fulfillment. I feel privileged to belong to a sisterhood of resilient, altruistic, and empowered women who grasp the intricacies of leadership in our current era. The mentorship and coaching I’ve received have been transformative, enriching both my leadership skills and personal growth,” said Dymeka Harrison.

Previously, Ms. Harrison served as Chief Commercial Officer at Foundation Medicine, where she led global clinical and commercial strategies for all product lines. Prior to that, she was Head of Strategic Marketing at Abbott Laboratories’ Rapid Diagnostics Division, overseeing global marketing efforts.

Ms. Harrison holds an Executive Master of Business Administration degree from Georgia Sate University, as well as Bachelor of Science in both Manufacturing Engineering as well as Computer Technology and Electronics Engineering from North Carolina A&T State University.

The Exceptional Women Alliance (EWA) is an invitation only peer mentorship organization where high-potential, high-level Exceptional Women from across multiple industries are hand-selected and invested in, to grow, learn, share, and succeed. In addition to the achievement of significant success, the criteria for acceptance include character traits that are defining of the EWA Culture – Kindness, the Spirit of Generosity, Transparency, Gratitude and Willingness to Share their Networks. The Foundation is a powerhouse of peer-to-peer mentoring that provides guidance, deep connection, and leadership, propelling each woman to sustainable success – one woman at a time. The year-long program enables each member to be connected as alumnae for life in the ever-expanding EWA global network, as their fellow women leaders continue to move into positions of significance.
Learn more at https://www.exceptionalwomenalliance.com/
Like us on Facebook

Media Contact

Larraine Segil, Exceptional Women Alliance, 3106781499, [email protected], www.exceptionalwomenalliance.com

Twitter LinkedIn

SOURCE Exceptional Women Alliance



Health

Greenlight Guru Celebrates 10 Years by Introducing its Multi-Product MedTech Suite

Leave a comment


Greenlight Guru Quality: The #1 QMS software, built to help MedTech companies improve speed and quality throughout the product lifecycle while lowering risk and costs.

Greenlight Guru Clinical (formerly SMART-TRIAL): The leading clinical data collection toolbox for MedTech, engineered to enable all clinical data operations within a single, compliant platform.

Greenlight Guru Academy: The premier destination for MedTech professionals looking for high-quality industry education and certifications.

“Greenlight Guru has been a great partner for our company,” says Kevin Coker, CEO and Co-Founder at Proxima CRO. “The solutions in the MedTech Suite have helped our clients get away from the old manual paper-based systems that have slowed them down in the past, and the platform’s intuitive design ensures that even novice users can hit the ground running from day one.”

Findings from the 2023 MedTech Industry Benchmark Report reveal that medical device companies face significant challenges when it comes to their critical quality process. One in three MedTech professionals say they are not well equipped to meet quality and product development objectives, and only 15% have a high level of visibility into quality problems. Additionally, 44% of MedTech companies use inadequate general-purpose tools to conduct critical clinical testing data collection.

Greenlight Guru’s MedTech Suite was built specifically to address these issues. An independent study found that Greenlight Guru Quality reduces the time needed to implement a QMS by 70% and reduces time spent on design and development documentation by 50%. Furthermore, Greenlight Guru Clinical allows MedTech professionals to quickly build custom clinical studies, reducing the time to set up a study by as much as two to three weeks. These gains in speed and efficiency can have a significant impact on a MedTech company’s ability to successfully get a product to market faster and keep it there over time.

“Over the past 10 years, we are proud to have helped over 1,100 MedTech companies bring innovative products to market that improved the quality of life for millions of people around the world,” says David DeRam, CEO of Greenlight Guru. “We are excited to continuously evolve our offering with the new MedTech Suite, delivering the most innovative solutions to help move MedTech forward.”

Greenlight Guru will be holding a webinar today at 9 a.m. ET to showcase the MedTech Suite and share the future roadmap for the solutions. You can watch the virtual event live or on-demand by registering at this link: https://www.greenlight.guru/10-years-launch-event.

About Greenlight Guru
Greenlight Guru is the leading connected, cloud-based platform purpose-built for MedTech companies. The end-to-end solution streamlines product development, quality management, and clinical data management by integrating cross-functional teams, processes, and data throughout the entire product lifecycle. Greenlight Guru’s platform is used by organizations across the globe that are replacing their disjointed, legacy tools and solutions to bring life-changing products to people faster and with less risk. For more information, visit https://www.greenlight.guru.

Media Contact

PR at Greenlight Guru, Greenlight Guru, (317) 960-4220, [email protected], https://www.greenlight.guru/

SOURCE Greenlight Guru

Health

DecisionHealth’s Association of Home Care Coding & Compliance (AHCC) announces winners of its 2023 Achievement Awards recognizing home health and hospice professionals.

Leave a comment


Home Health OASIS Consultant of the Year: Celeste Miller, RN, BS, HCS-D, COS-C, director of operations at Oracle. Celeste is also a member of AHCC’s BMSC exam committee. In her nomination a colleague said, “When I think about quality and compliance, Celeste is the first name that comes to mind.”

Home Health OASIS Professional of the Year: Kea Wormsley, RN, BSN, COS-C, nurse clinical reviewer and educator for Douglas County VNA. She was recognized for outstanding attributes and responsibility for OASIS accuracy. A colleague who nominated Kea added, “I’ve never met a more dedicated, detail-oriented nurse.”

Hospice Coding Professional of the Year: Nanette Minton, RN, HCS-D, HCS-H, HCS-O, senior clinical coding manager with MAC Legacy. Nanette sits on AHCC’s Advisory Board and BMSC exam committee. She was recognized for “…her skill at applying complex coding principles in a practical, relatable way that benefits hospice providers by strengthening compliance.”

Home Health Coding Professional of the Year: Arlynn Hansell, PT, HCS-D, HCS-O, HCS-H, COS-C, is a former AHCC Board member, committee member, and retiree extraordinaire who is the director of the education, coding, and OASIS division at SimiTree. This honor was best summarized by a colleague: “Our agency is truly blessed having had Arlynn to guide us all in the right direction.”

All winners were peer nominated and embody AHCC’s mission “to serve as the premier compliance and coding community for home care agencies, providing a medium for education, professional growth, advocacy, and networking.”

Milliman added, “It truly is an honor to acknowledge the contributions of these individuals to their organization, local home care communities, the larger national Association, and the profession globally due to their initiatives and work ethic.”

About AHCC

 The Association of Home Care Coding & Compliance (AHCC) aims to serve the staff-development needs of the home care industry through education, training, work tools, resources, community building/networking, and advocacy. AHCC also offers professional certifications for coders and clinicians through the Board of Medical Specialty Coding & Compliance (BMSC). Learn more at https://ahcc.decisionhealth.com.

About DecisionHealth

DecisionHealth, an HCPro brand, is the industry’s leading source for home health agencies and medical practice facilities to receive the latest news, analysis, and regulatory guidance on Medicare coding and reimbursement, benchmarks, payments, and HIPAA compliance through its flagship publications, as well as a wide selection of coding books, educational events, and online tools. Visit http://www.decisionhealth.com.

Media Contact

Press Team, DecisionHealth, 1-978-624-4568, [email protected], https://www.decisionhealth.com/ 

Customer Service, DecisionHealth, 1-855-225-5341, [email protected], https://ahcc.decisionhealth.com/ 

SOURCE DecisionHealth

Health

Splash Clinical Achieves Record Growth Supported by Innovative Patient Recruitment Tools

Leave a comment


In the last three years, Splash Clinical has seen a remarkable revenue growth of 429%, bolstered its workforce by 82%, and expanded its global presence to the APAC region. This significant momentum is a testament to the company’s commitment to the acceleration and success of clinical trials worldwide. Splash Clinical’s surge in growth underscores the essential role the company plays in expediting clinical trials. Every delay in a clinical study can potentially push back the release of vital treatments to patients who need them. Splash’s Clinical growth is tangibly impacting the speed and efficiency of drug development and delivery.

A critical factor in this success is Splash Clinical’s innovative approach to patient recruitment.

“At Splash Clinical, we’ve redefined patient recruitment by tapping into the power of social media, digital media, mobile technologies, and real-time analytics,” said Matt Teuteberg, President and CEO of Splash Clinical. “This has enabled patients from around the world to discover clinical studies effortlessly while scrolling through their feeds, helping us fulfill our ultimate goal: helping our clients meet their recruiting goals quickly and consistently.”

One of the innovations behind this growth is Splash Clinical’s call center service, designed to perform secondary phone screenings of patients and direct them to appropriate trial sites. The service aims to relieve some of the burden on sites already tasked with the complexities of managing clinical trials. Unlike similar services from competitors, Splash Clinical’s call center leverages advanced scheduling technology, analytics for targeted screenings, and a “white glove” approach that includes trial education support for patients. According to company metrics, the call center has contributed to a 69% increase in screening rates for sites that use the service. This increase is significant for the efficiency of both the sites and the studies involved. This tool aligns perfectly with Splash Clinical’s mission of prioritizing patients and offering a seamless enrollment experience.

Splash’s commitment to combining advanced technology with genuine empathy provides a unique edge in patient recruitment. Moreover, precision targeting remains a central component of Splash Clinical’s strategy. The company believes in creating clinical studies that mirror the diverse world we live in to address health disparities. By creating campaigns that resonate with patients in diverse geographies, Splash Clinical can engage with patients effectively and enroll them in studies tailored to their unique needs.

With a history of providing high-quality referrals and enrolling patients in clinical studies across the globe, Splash Clinical’s continued growth and innovative features solidify its position as a trailblazer in patient recruitment.

To learn more, please visit splashclinical.com/

About Splash Clinical

Splash Clinical is the new standard in patient recruitment solutions. We transform recruitment processes, setting a new benchmark for the industry. Combining the powers of digital media, mobile technologies, social media, and real-time analytics, our unique recruiting methodology has successfully expedited enrollment for clinical studies worldwide.

Splash Clinical delivers precision-targeted patient recruitment strategies, meeting the unique demands of Sponsors, Contract Research Organizations (CROs), and Sites. We ensure that our partners can focus on the vital task of advancing medical research while we take care of securing high-quality patient referrals for each study. With transparency embedded into our approach, we provide clients with real-time performance insights, stripping the recruitment landscape of any surprises.

While we employ cutting-edge digital solutions, our real edge comes from our people-centric approach. At the heart of Splash Clinical is a team that goes above and beyond to understand our clients’ needs, providing a level of service that sets us apart from the competition. As a result, we deliver personalized services and foster strong relationships in the pursuit of accelerating clinical research to improve human health.

Splash Clinical was founded in 2011 and is proudly based in Wauwatosa, WI. To learn more, please visit https://splashclinical.com/.

Splash Clinical. Redefining Patient Recruitment.

Media Contact

Juan Avila, Splash Clinical, 5125894486, [email protected], https://splashclinical.com/

SOURCE Splash Clinical

Health

Rev1 Ventures Launches $30 Million Fund, the Third to Support Research-Based Healthcare Innovation

Leave a comment


“Building on our collective experience, and proven track record supporting life sciences companies, Rev1 Catalyst Fund III represents another unique opportunity to help commercialize breakthrough technologies and transform many critical aspects of health care,” said Tom Walker, President and CEO of Rev1 Ventures. “Between Rev1, Ohio State, and Nationwide Children’s Hospital, our team has led nearly 100 spinouts from over 20 research institutions and corporations and brings the expertise and financing to help life sciences companies build the right team and infrastructure that allows them to scale and grow.”

To date, Rev1 Catalyst Fund II has invested more than $10 million since launching in 2019, investing in eight unique companies across 16 financial rounds that have raised over $100 million in co-investment and follow-on investment. Rev1 Catalyst Fund and Rev1 NCH Fund have generated more than $450 million in exits, including the acquisitions of Celenex, Myonexus, and Deep Lens.

“Ohio State values the collaborative approach to accelerate innovation and support life science innovators in our community,” said Peter Mohler, Acting President and Executive Vice President for Research, Innovation and Knowledge at Ohio State. “This fund will support groundbreaking advancements and help build successful companies that are working to positively impact people’s lives.”

“Clarametyx, a Nationwide Children’s spin-off and biotechnology company developing groundbreaking therapies and vaccines for life-threatening bacterial infections, is making important strides thanks, in part, to capital raised from Rev1 Catalyst Fund II, and we are already seeing the impact of fueling innovations like this in the market,” said Tim Robinson, Chief Executive Officer at Nationwide Children’s Hospital. “By bringing together research institutions, investors, and strategic advisors, we’re elevating Central Ohio’s position in the industry and helping to bring more life-saving solutions to the world.”

Rev1 Catalyst Fund III will invest in nearly a dozen companies over the next five years, with plans to support follow-on funding for successful predecessor fund portfolio company rounds. For more information about the fund and Rev1 Ventures, visit https://www.rev1ventures.com/our-companies/.

About Rev1 Ventures
Rev1 Ventures accelerates innovation with connections and capital that help entrepreneurs build high-growth tech companies in software, healthcare, and more. Its venture studio platform serves entrepreneurs at their earliest stages while aligning with corporate and research partners to validate customers, build teams, and access funding. Rev1 is changing the equation for startup success and putting Central Ohio on the map as one of the fastest-growing innovation ecosystems in the country. For more information, visit http://www.rev1ventures.com.

About The Ohio State University
The Ohio State University is a top-ranked flagship public research university with a nationally recognized academic medical center. The university offers more than 200 majors — plus 500 specializations— for undergraduates to explore, along with 230 master’s, doctoral and professional degree programs. Across all campuses, Ohio State enrolls nearly 68,000 students in 15 colleges and supports more than 300 academic and interdisciplinary research centers and institutes. With a dynamic and engaged group of more than 580,000 living alumni and extensive partnerships locally and globally, Ohio State has an unparalleled capacity to bring people together and provide expertise and resources to create solutions to the problems the world is facing now.

About Nationwide Children’s Hospital
Named to the Top 10 Honor Roll on U.S. News & World Report’s 2023-24 list of “Best Children’s Hospitals,” Nationwide Children’s Hospital is one of America’s largest not-for-profit free-standing pediatric health care systems providing unique expertise in pediatric population health, behavioral health, genomics and health equity as the next frontiers in pediatric medicine, leading to best outcomes for the health of the whole child. Integrated clinical and research programs, as well as prioritizing quality and safety, are part of what allows Nationwide Children’s to advance its unique model of care. Nationwide Children’s has a staff of more than 14,000 that provides state-of-the-art wellness, preventive and rehabilitative care and diagnostic treatment during more than 1.7 million patient visits annually. As home to the Department of Pediatrics of The Ohio State University College of Medicine, Nationwide Children’s physicians train the next generation of pediatricians and pediatric specialists. The Abigail Wexner Research Institute at Nationwide Children’s Hospital is one of the Top 10 National Institutes of Health-funded free-standing pediatric research facilities. More information is available at NationwideChildrens.org.

MEDIA CONTACT:
Aimée Eichelberger
[email protected]

SOURCE Rev1 Ventures

Health

Oxford Performance Materials Creating Separate Entity for its Orthopedic Implant Business

Leave a comment


Oxford Performance Materials, Inc. (OPM; https://oxfordpm.com/), an industry leader in PEKK polymer science and high performance additive manufacturing, is establishing a focused entity for its 3D printed orthopedic business areas following the company’s further expansion into personalized implants. The decision to create a separate orthopedic company will allow greater focus, investment and resources to this high-growth sector of OPM’s business.

SOUTH WINDSOR, Conn., Sept. 19, 2023 /PRNewswire-PRWeb/ — Oxford Performance Materials, Inc. (OPM; https://oxfordpm.com/), an industry leader in PEKK polymer science and high performance additive manufacturing, is establishing a focused entity for its 3D printed orthopedic business areas following the company’s further expansion into personalized implants. The decision to create a separate orthopedic company will allow greater focus, investment and resources to this high-growth sector of OPM’s business.

OPM first began 3D printing cranial and facial implants in 2014, and has delivered patient-matched devices for over 4,500 craniomaxillofacial (CMF) cases to date. The company has six FDA 510(k) clearances.

Until now, surgeons in need of personalized implants for cases in lower & upper extremity, trauma and oncology have had to rely upon 3D printed titanium devices, with recognized drawbacks of stiffness (resulting in stress-shielding and adjacent bone loss), an inability to modify the implant in the O.R., long delivery times, no anti-bacterial properties, poor imaging, and eventual implant corrosion in the body. Like titanium, 3D printed PEKK structures exhibit excellent bone ongrowth, however in contrast, OPM’s 3DP PEKK exceeds titanium in the following ways:

  • A material with bone-like mechanical properties that is fully modifiable in the OR
  • Anti-bacterial properties
  • Corrosion-free
  • Radiolucent
  • Shorter manufacturing times

Analysts tracking the medical device markets consistently report 3D printed implants among the highest growth sectors in orthopedics, and personalized devices are the orthopedic segment experiencing hyper-growth.

“Since our inception in 2000, OPM has been quietly building the most advanced materials and additive manufacturing technology in the orthopedic industry,” said Scott DeFelice, founder & CEO. “Our extension into personalized orthopedic implants began last year, providing devices pro-bono in response to an urgent need in Ukraine. Once specialized surgeons in the U.S. and Europe became aware of the comprehensive solution offered by 3DP PEKK, OPM’s extension from patient-matched CMF to an extended set of personalized devices was a natural step. We have a tiger by the tail here, and the broader decision to separate out our orthopedic offerings will allow greater focus and resources to better serve these customers.”

About Oxford Performance Materials, Inc.

Oxford Performance Materials, Inc. (OPM) was founded in 2000 to develop and commercialize the world’s highest performing thermoplastic, PEKK (poly-ether-ketone-ketone). OPM’s Materials business has developed a range of proprietary, patented technologies for the synthesis and modification of a range of PAEK polymers that are sold under its OXPEKK® brand, including coating technologies for a range of industrial and biomedical applications. OPM is a pioneer in 3D printing. OPM’s OsteoFab® technology is in commercial production in numerous orthopedic implant applications, including cranial, facial, spinal, and sports medicine devices, and OPM’s OXFAB® production parts are designed for highly demanding industrial applications.

Business or Media Inquiries to Oxford Performance Materials:

Bernard Plishtin

Oxford Performance Materials, Inc.

917.494.3649

[email protected]

Media Contact

Vincent DeFelice, Oxford Performance Materials, Inc, 1 4135528304, [email protected], www.oxfordpm.com

SOURCE Oxford Performance Materials, Inc

Health: Psychology

Cayman Chemical Receives CEP for Latanoprost API from EDQM

Leave a comment


Cayman Chemical, a world leader in the manufacture of prostaglandins for both research use and as active pharmaceutical ingredients (APIs), has been granted a CEP for its latanoprost API. Cayman Chemical is the first company in the USA to receive a CEP for latanoprost.

ANN ARBOR, Mich., Sept. 19, 2023 /PRNewswire-PRWeb/ — Cayman Chemical, a world leader in the manufacture of prostaglandins for both research use and as active pharmaceutical ingredients (APIs), has been granted a Certification of Suitability to the monographs of the European Pharmacopoeia (CEP) by the European Directorate for the Quality of Medicines and HealthCare (EDQM) for its latanoprost API, effective August 28th, 2023. Cayman Chemical is the first company in the USA to receive a CEP for latanoprost.

A CEP is granted to a manufacturer of an active substance that has demonstrated that the chemical purity and microbiological quality of their substance is adequately controlled by the relevant European Pharmacopoeia monograph and meets European Union (EU) pharmaceutical legislation requirements.

A CEP harmonizes data exchange between regulatory agencies and industry. It confirms that the active substance produced by the manufacturer has met quality standards under Good Manufacturing Practices (GMPs) that make it appropriate and safe for use in medicines. A CEP may be used to simplify the drug application process, as the CEP can be used in the application dossier for marketing authorization, making it easier to receive approval from licensing authorities.

CEPs are recognized by the signatory parties of the Convention on the Elaboration of a European Pharmacopoeia, which includes all European Pharmacopoeia member states and the EU. They are also accepted (some with conditions) by other countries and regulatory authorities. The EDQM has also established a list of authorities and organizations that are allowed access to certification assessment and/or inspection reports from manufacturer sites.

More information on APIs for commercial distribution available from Cayman, including latanoprost, may be found online at http://www.caymanchem.com/apis/overview.

Media Contact

Bryanna Degenhardt, Cayman Chemical, 7349753913, [email protected], www.caymanchem.com

SOURCE Cayman Chemical

Health: Mental Health

Surfacide® Announces Exclusive Distribution of PathTrac®, A Cutting-Edge Clinical Decision Support Software Platform

Leave a comment


PathTrac features include:

  • Reservoir Monitoring
  • Bacterial Strains Identification
  • Transmission Mapping
  • Easy to use sampling kits, swabbing takes only minutes
  • Virtual Training
  • Cloud Database and Connectivity

“We are honored to partner with RDB Bioinformatics and be the exclusive provider of PathTrac to hospitals around the country,” said Gunner Lyslol, Founder & CEO of Surfacide. “Optimizing OR hygiene protocols with this important technology prioritizes patient safety and has the ability to significantly reduce the risk of SSI’s and HAI’s, which is costing the healthcare industry more than $6.5 billion each year.”

“At RDB Bioinformatics, we are passionate about our partnership with Surfacide, and having them be the conduit to bringing PathTrac into healthcare facilities. We have an active interest in each other’s separate companies initiatives, while working together to develop shared success in keeping patients safe,” added Dr. Randy Loftus, Co-founder and Chief Medical Officer of RDB Bioinformatics, the owner of PathTrac.

Surfacide is proud to announce its partnership with PathTrac at the OR Manager Conference in Nashville, Tennessee September 18-20 (Booth #926). To learn more about transmission pathways specific to your OR, stop by our booth or get in touch with [email protected] to have a Surfacide consultant set up a baseline assessment of your facility.

PathTrac Video: HERE

Surfacide press kit: HERE

About Surfacide:

Founded in 2010, Surfacide is a UV technology and infection solutions company producing scientifically proven, hospital-grade UV devices. Surfacide’s award-winning Helios® System is the world’s only patented, triple emitter ‘robotic’ UV-C light solution to rapidly reduce bioburden and microorganisms. A trusted partner in infection prevention, Surfacide has been deployed in over 1000 leading hospitals and healthcare facilities worldwide. Surfacide LLC is proud to be American-made and manufactured in Waukesha, WI. Visit the Surfacide website to learn more or contact one of our professional support specialists at (844)-390-3538.

About RDB Bioinformatics:

RDB Bioinformatics is focused on helping patients, hospitals, and the medical community to work together to address HAIs and increasing bacterial resistance. Our primary goals are to address the goals put forth by the Centers for Disease Control including prevention of infections for patients undergoing surgery, prevention of bacterial spread between patients, and improving antibiotic stewardship. Our overarching goal is to maximize patient safety today and for the future, preventing high risk OR bacterial transmission and infection development. https://www.pathtrac.com

Media Contact

Alexandra Skillman, Surfacide, 1 4153426425, [email protected], www.surfacide.com

SOURCE Surfacide

Health: Addiction

United Breast Cancer Foundation Executive Director, Stephanie Mastroianni, Honored at Twisted Pink Annual Gala

Leave a comment


Stephanie Mastroianni’s leadership at UBCF and her unyielding commitment have elevated her as a deserving recipient of the Dace Polk Brown Ambassador Award. Stephanie’s influence and the dedication of the entire UBCF team have provided inspiration and empowerment to countless individuals within the breast cancer community nationwide.

UBCF Executive Director, Stephanie Mastroianni shared, “In over twenty years of working in the breast cancer arena, I have seen first hand what is possible when individuals and organizations focus on doing good in the world, one step at a time. Every day is an opportunity to make a difference, and my commitment remains strong. I am proud of the work my team at UBCF does and I am grateful to work alongside the team at Twisted Pink.”

UBCF’s commitment to serving breast cancer patients and survivors was demonstrated through their sponsorship of 17 metastatic breast cancer patients, along with their respective guests, who attended the gala free of charge. This gesture of kindness and solidarity showcased UBCF’s commitment to standing with breast cancer patients and their families through every step of their journey.

Twisted Pink’s Founder and Executive Director, Caroline Johnson shared, “Stephanie Mastroianni and UBCF truly embody the spirit of our mission. Their support has touched lives and brought awareness to the challenges of breast cancer. We are proud to have them as partners.” Johnson continued, “The synergy between Twisted Pink and United Breast Cancer Foundation has been a beacon of hope for those affected by breast cancer. Together, we have shown that by combining resources and compassion, we can make a tangible difference.”

United Breast Cancer Foundation’s work with Twisted Pink is truly a testament to the power of collaboration and community. The Twisted Pink Annual Gala was a success, thanks to the collaborative efforts of UBCF and the compassionate individuals behind the scenes. The event was a heartwarming celebration of resilience and support, leaving a lasting impression of unity and determination. Everyone present was reminded that together, we can create positive change in the fight against breast cancer.

About United Breast Cancer Foundation:
The United Breast Cancer Foundation is a non-profit founded in 2000 with a mission to make a positive difference in the lives of those impacted by breast cancer. UBCF is committed to funding breast health and wellness services focused on cancer prevention, screening, treatment, overall wellness and beyond. The platinum rated charity offers numerous life-supporting patient and family programs available to women, men, and families nationwide. Tax-deductible contributions may be made towards UBCF’s programs. UBCF accepts contributions through Donor Advised Funds and vehicle and property donations as well. Combined Federal Campaign #77934. http://www.ubcf.org

About Twisted Pink:
Since 2014, Twisted Pink’s efforts have been to provide advocacy and educational programs about metastatic breast cancer. They have been at the forefront of over 3 million dollars supporting metastatic breast cancer research. Twisted Pink’s mission is to provide hope and connectivity to individuals living with metastatic breast cancer and to fund bold breakthroughs in research and awareness of the disease. http://www.twistedpink.org.

Media Contact

Beth Reichart, United Breast Cancer Foundation, 8778224287, [email protected], ubcf.org

Twitter LinkedIn

SOURCE United Breast Cancer Foundation